BIVI - BIVI 4-DAY DEADLINE ALERT: Hagens Berman National Trial Attorneys Encourages BioVie (BIVI) Investors with Substantial Losses to Contact Firm Before Mar. 19th Deadline in Securities Class Action | Benzinga
SAN FRANCISCO, March 18, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges BioVie Inc. (NASDAQ:BIVI) investors who suffered substantial losses to submit your losses now.
| Class Period: Aug. 5, 2021 – Nov. 29, 2023 |
| Lead Plaintiff Deadline: Mar. 19, 2024 |
| Visit: www.hbsslaw.com/investor-fraud/BIVI |
| Contact An Attorney Now: |
| BIVI@hbsslaw.com |
| 844-916-0895 |
BioVie Inc. (BIVI) Securities Class Action:
The litigation focuses on the propriety of BioVie's disclosures concerning its adherence to Good Clinical Practice ("GCP") and protocols related to its Phase 3 clinical trial of NE3107, a potential Alzheimer's disease drug.
On Aug. 5, 2021, BioVie announced that it enrolled the first patient in its Phase 3 clinical trial of NE3107 and thereafter assured investors that the "[t]rial continues to have a good safety profile and low discontinuation rate." On Sep. 26, 2023, BioVie announced completion of the last treatment visit in the trial and investors eagerly awaited the results for a drug, which the company touted as having a "10+ billion annual peak sales potential."
The complaint alleges BioVie made misleading statements and concealed that: (1) BioVie was not conducting proper oversight of its Phase 3 clinical trial; (2) the COVID-19 pandemic significantly and negatively ...
BIVI) Investors with Substantial Losses to Contact Firm Before Mar. 19th Deadline in Securities Class Action>Full story available on Benzinga.com